(143 days)
Not Found
No
The summary describes a reagent used in flow cytometry to identify and enumerate specific cell populations based on antibody binding and fluorescence. There is no mention of algorithms, machine learning models, or any computational analysis beyond standard flow cytometry data processing (gating, counting). The performance studies focus on accuracy, linearity, and precision of the reagent and the flow cytometry process itself, not on the performance of any AI/ML component.
No.
The device is used to identify and enumerate lymphocyte populations in whole blood as an aid in diagnosis and monitoring of disease states, not for direct treatment.
Yes
The text explicitly states that the device's measurements "may be used as aids to evaluate immune competency underlying known or unknown disease states and to monitor lymphocyte levels following organ transplantation," and "may aid in the diagnosis and/or prognosis of immunodeficiency disease." This indicates its use in aiding the diagnosis or prognosis of medical conditions.
No
The device is a reagent comprised of monoclonal antibodies labeled with fluorochromes, intended for use in flow cytometry. This is a physical product, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the reagent is used for the "simultaneous identification of total CD3+ and CD19+ lymphocytes in whole blood by flow cytometry." It also mentions that the results "may be used as aids to evaluate immune competency underlying known or unknown disease states and to monitor lymphocyte levels following organ transplantation." This clearly indicates the device is intended for use in the diagnosis or treatment of disease or other conditions.
- Sample Type: The device is used with "whole blood," which is a human specimen.
- Method: The analysis is performed "by flow cytometry," which is a laboratory technique.
- Regulatory Context: The presence of a "Predicate Device(s)" section with a K number (K926124) strongly suggests that this device is being submitted for regulatory clearance as an IVD.
All these points align with the definition of an In Vitro Diagnostic device, which is a medical device intended for use in vitro for the examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the compatibility of human tissues.
N/A
Intended Use / Indications for Use
CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 Monoclonal Antibody Reagent is a three-color fluorescent reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. The reagent allows simultaneous identification of total CD3+ and CD19+ lymphocytes in whole blood by flow cytometry. An isotypic control, CYTO-STAT® triCHROME™ CD45-FITCMsIgG1-PCS, is used to monitor nonspecific staining.
CYTO-STAT® triCHROME™ CD45-FITCMsIgG1-RD1/MsIgG1-PC5 Isotypic Control is a three-color fluorescent reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. This product is intended for use as a quality control reagent to monitor the levels of nonspecific antibody binding in cell surface staining procedures which use CYTO-STAT® triCHROME™ Monoclonal Antibody Reagents comprised of CD45-FITC and two MsIgG1 subclass monoclonal antibodies conjugated to RD1 and PC5.
CD3+ and/or CD19+ lymphocyte percentages and absolute counts may be used as aids to evaluate immune competency underlying known or unknown disease states and to monitor lymphocyte levels following organ transplantation.
To illustrate, identification of abnormal levels of CD3+ lymphocytes may aid in the diagnosis and/or prognosis of unidentified disease conditions in patients with low white blood cell counts. Measurement of CD3+ and/or CD19+ lymphocytes, in conjunction with CD4+ (inducer) and CD8+ (suppressor/cytotoxic) T lymphocytes and corresponding T4/T8 ratios, may aid in the diagnosis and/or prognosis of immunodeficiency disease such as infection with human immunodeficiency virus (HIV), the etiologic agent of acquired immunodeficiency syndrome (AIDS). Altered percentages of CD3+ lymphocytes recorded following organ (for example, kidney, hear, liver, lung) transplantation suggests T and/or B Jymphocyte quantitation may be useful as an aid in monitoring these cellular populations.
As part of a Three Color Lymphocyte Immunophenotyping Panel which includes the NK (Natural Killer) lymphocyte reagent, CYTO-STAT® triCHROME™ CD45-FITC/CD56-RD1/CD3-PCS, CYTO-STAT® triCHROME™ CD45-FITC/CD19-RDI/CD3-PC5 provides the ability to comprehensively identify and enumerate an individual's major lymphocyte subsets: T. B and NK. The reagent also functions as a quality control check for a specimen in terms of total lymphocyte percentage and CD3+ lymphocyte measurements across the panel.
Product codes (comma separated list FDA assigned to the subject device)
GKZ
Device Description
CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 is a three-color fluorescent reagent comprised of three murine monoclonal antibodies. Each antibody is labeled with a different color fluorochrome. The reagent allows simultaneous identification and enumeration of total CD3+ and CD19+ lymphocytes in whole blood by flow cytometry. An isotypic control. CYTO-STAT® triCHROME™ CD45-FITC/MsIgG1-RD1/MsIgG1-PC5, is used to monitor nonspecific staining.
CYTO-STAT® triCHROME CD45-FITC/MsIgG1-PC5 is a three-color fluorescent reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. This product is intended for use as a quality control reagent to monitor the levels of nonspecific antibody binding in cell surface staining procedures which use CYTO-STAT® triCHROME™ Monoclonal Antibody Reagents comprised of CD45-FITC and two monoclonal antibodies of the MsIgG1 subclass conjugated to RD1 and PC5.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Product Testing:
- Accuracy: Normal and abnormal whole blood specimens were collected from geographically diverse populations of males and females unselected as to race and ranging in age from 19 to 84 years. Specimens were divided, processed as lysed preparations and assayed in parallel with CD45/CD19/CD3 and CD3/B4. CD3+ and CD19+ percentages expressed in terms of the total lymphocyte count and absolute counts (cells/uL) were determined with COULTER® EPICS® XL-MCL™ flow cytometers gated on lymphocytes. White blood cell counts and 5-part differentials were obtained for all specimens. Results analyzed in terms of minimums, maximums, means ± 1 SD, confidence intervals, regression analyses and analyses of variance demonstrated that CD45/CD19/CD3 and CD3/B4 identify and enumerate essentially identical numbers of the targeted lymphocytes in whole blood specimens.
- Linearity: Three replicate measurements were made on a concentrated COULTER™ CYTO-TROL Cells sample serially diluted to achieve a range of CD3+ and CD19+ lymphocyte concentrations. Samples were assayed with CD45/CD19/CD3 and analyzed on a COULTER® EPICS® XL-MCL™ flow cytometer gated on lymphocytes. Values were expressed in terms of absolute count (cells/uL). Results analyzed in terms of regression and correlation analyses for recovered vs. expected absolute counts demonstrated Linearity of the assay.
- Precision: Within Run (Intralaboratory): Ten replicate measurements were made for each of three levels of CD3+ and CD19+ lymphocyte concentrations on the same day using a COULTER® EPICS® XL-MCL™ flow cytometer gated on lymphocvtes. Levels were obtained by selective sreening of normal whole blood specimens and assayed with CD45/CD19/CD3. Values were expressed in terms of percentage of the total lymphocyte count. Results analyzed in terms of mean ± 1 SD and CV demonstrated Within Day (Intralaboratory) Precision of the assay.
- Precision (Interlaboratory): Ten replicate measurements on were made on the same day using different laboratories and COULTER® EPICS® XL-MCL™ flow cytometers. All measurements were made on a single normal whole blood specimen divided and assayed with CD45/CD19/CD3. Values were expressed in terms of percentage of the total lymphocyte count. Results analyzed in terms of mean ± 1 SD and CV demonstrated Interlaboratory Precision of the assay.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”
0
NOV Coulter Corporation P.O. BOX 169015 Date: June 17, 1998 Miami, Florida 33116-9015 USA Summary of Safety and Effectiveness Information For 510(k) Premarket Notification Customer Service: (800) 526-7694 Title: Product Information: (800) 526-6932 (800) 327-6531 (305) 327-6531 (005) 621-021 Product: CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 Monoclonal Antibody Reagent Coulter Commenton with Miami, Florida USA CYTO-STAT® triCHROME™ CD45-FITC/MsIgG1-RD1/MsIgG1-PC5 Isotypic Control Courter Leaging Corporation Mami, Horida USA Coulter Corporation Company: Coulter Electronics, Ply. Ltd. 11800 SW 147 Avenue Sydney, Australia Miami, FL 33196-2500 Coulter Electronics Inc. & Com , Ltda Rio de Janeiro, Brazil Contact: Dr. Marion S. Gaide (M/C: 31-B06) Coulter Electronics of Canada, Ltd. Senior Regulatory Affairs Specialist Burlington, Ontario. Ganada Corporate Regulatory Affairs Coulter Flactronics, I td. Luton Bestordshire, England Telephone: (305) 380-2594 Coultronics France, S.A. Margency, France Common or Usual or Classification Name: Lymphocyte Immunophenotyping Monoclonal Coulter Electronics GmbH Antibody Reagent with Isotypic Control Krefeld, Germany Coulter Electronics (HK), Ltd. Product Classification: Product Code: GKZ; C.F.R. Section: 864.5220; Classification Hong Kong Panel: Hematology and Pathology Devices; Device Class: II Coulter K. K Tokyo, Japan Intended Use: Coulter de Mexico S.A., DE C.V. CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 is a three-color fluorescent reagent Mexico City, Mexico comprised of three murine monoclonal antibodies. Each antibody is labeled with a different color Couler Eecronis, Lt. fluorochrome. The reagent allows simultaneous identification and enumeration of total CD3+ and Midrecht Netherlands CD19+ lymphocytes in whole blood by flow cytometry. An isotypic control. CYTO-STAT® Coulter Geotronics, Pty, Ltd. triCHROME™ CD45-FITC/MsIgG1-RD1/MsIgG1-PC5, is used to monitor nonspecific staining. Auckland, New Zealand
Couter Partices Sales of B. Inc. CYTO-STAT® triCHROME CD45-FITC/MsIgG1-PC5 is a three-color fluorescent Son Juan, Puerto Rico, reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. This product is intended for use as a quality control reagent to monitor the levels of nonspecific antibody binding in cell surface staining procedures which use CYTO-STAT® triCHROME™ Monoclonal Antibody Reagents comprised of CD45-FITC and two monoclonal antibodies of the MsIgG1 subclass conjugated to RD1 and PC5.
Substantial Equivalence: 510(k) Premarket Notification: K926124 CYTO-STAT®/COULTER CLONE® CD3(1gG1)-FITC/B4-RD1 Monoclonal Antibody Reagent with CYTO-STAT®/COULTER CLONE® MsIgG1-RD1/MsIgG1-FITC Isotypic Control
Product Comparison:
The CD45/CD19/CD3 and CD3/B4 systems are essentially identical with respect to features and principles of operation. Each liquid reagent allows simultaneous identification and enumeration of more than one lymphocyte population (CD3+ and CD19+) in a single specimen using a single reagent. Each system also requires an isotypic control to monitor nonspecific binding. The difference between the systems is that CD45/CD19/CD3 contains CD45 to identify a lymphocyte gate for making CD3+ and CD19+ measurements. CD3/B4 requires a separate reagent, CYTO-STAT®/COULTER CLONE® Mo2-RD1/KC56 (T-200)-FITC, for this purpose. MAb Conjugation: CD45: FITC (Fluorescein Isothiocyanate). CD19: RD1 (Phycoerythrin). CD3: PC5 (Phycoerythrin-Cy5).
Courter Electronios, Ltd.
Con ter Decronics, Ud.
Man" de To
BECT PHOSE
Johannesburg, Soula Africa
1998
1
- Product testing to assess the performance of CD45/CD19/CD3 is described below. Studies were Product Testing: designed in line with instructions for use in the product package insert and performance specifications. Specimens were assayed with CD3/B4 for comparison purposes. The results of product testing demonstrated that CD45/CD19/CD3 meets all performance specifications and provides mature T (CD3+) and B (CD19+) lymphocyte values comparable to those of CD3/B4.
-
- Accuracy:
-
Normal and abnormal whole blood specimens were collected from geographically diverse populations of males and females unselected as to race and ranging in age from 19 to 84 years. Specimens were divided, processed as lysed preparations and assayed in parallel with CD45/CD19/CD3 and CD3/B4. CD3+ and CD19+ percentages expressed in terms of the total lymphocyte count and absolute counts (cells/uL) were determined with COULTER® EPICS® XL-MCL™ flow cytometers gated on lymphocytes. White blood cell counts and 5-part differentials were obtained for all specimens.
Results analyzed in terms of minimums, maximums, means ± 1 SD, confidence intervals, regression analyses and analyses of variance demonstrated that CD45/CD19/CD3 and CD3/B4 identify and enumerate essentially identical numbers of the targeted lymphocytes in whole blood specimens.
-
- Linearity:
Three replicate measurements were made on a concentrated COULTER™ CYTO-TROL Cells sample serially diluted to achieve a range of CD3+ and CD19+ lymphocyte concentrations. Samples were assayed with CD45/CD19/CD3 and analyzed on a COULTER® EPICS® XL-MCL™ flow cytometer gated on lymphocytes. Values were expressed in terms of absolute count (cells/uL).
- Linearity:
Results analyzed in terms of regression and correlation analyses for recovered vs. expected absolute counts demonstrated Linearity of the assay.
-
- Precision: Within Run (Intralaboratory):
Ten replicate measurements were made for each of three levels of CD3+ and CD19+ lymphocyte concentrations on the same day using a COULTER® EPICS® XL-MCL™ flow cytometer gated on lymphocvtes. Levels were obtained by selective sreening of normal whole blood specimens and assayed with CD45/CD19/CD3. Values were expressed in terms of percentage of the total lymphocyte count.
- Precision: Within Run (Intralaboratory):
Results analyzed in terms of mean ± 1 SD and CV demonstrated Within Day (Intralaboratory) Precision of the assay.
-
- Precision (Interlaboratory):
Ten replicate measurements on were made on the same day using different laboratories and COULTER® EPICS® XL-MCL™ flow cytometers. All measurements were made on a single normal whole blood specimen divided and assayed with CD45/CD19/CD3. Values were expressed in terms of percentage of the total lymphocyte count.
- Precision (Interlaboratory):
Results analyzed in terms of mean ± 1 SD and CV demonstrated Interlaboratory Precision of the assay.
Marian S. Gaide, Ph.D.
Marion S. Gaide, PH.D. Senior Regulatory Affairs Specialist Corporate Regulatory Affairs
June 17, 1998
Date
2
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with a wing-like shape above them.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
9 1998 NOV
Dr. Marion S. Gaide Senior Regulatory Affairs Specialist COULTER CORPORATION 11800 SW 147 Avenue Mail Code 31-B06 Miami, FL 33196-2500
K982167 Re: Trade Name: CYTO-STAT triCHROME CD45-FITC/CD19-RD1/CD3-PC5 Monoclonal Antibody Reagent with CYTO-STAT triCHROME CD45-FITC/MsIqG1-RD1/MsIgG1-PC5 Isotypic Control Requlatory Class: II Product Code: GKZ Dated: September 29, 1998 Received: October 01, 1998
Dear Dr. Gaide:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. this response to your premarket notification Please note: submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
3
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a leqally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.qov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
INDICATIONS FOR USE
K 983167
510(k) Number (if known): Not Yet Assigned
CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 Monoclonal Antibody Reagent Device Name: with CYTO-STAT® triCHROME™ CD45-FITC/MsIgG1-RD1/MsIgG1-PC5 Isotypic Control
Indications For Use:
CYTO-STAT® triCHROME™ CD45-FITC/CD19-RD1/CD3-PC5 Monoclonal Antibody Reagent is a three-color fluorescent reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. The reagent allows simultaneous identification of total CD3+ and CD19+ lymphocytes in whole blood by flow cytometry. An isotypic control, CYTO-STAT® triCHROME™ CD45-FITCMsIgG1-PCS, is used to monitor nonspecific staining.
CYTO-STAT® triCHROME™ CD45-FITCMsIgG1-RD1/MsIgG1-PC5 Isotypic Control is a three-color fluorescent reagent comprised of three murine monoclonal antibody is labeled with a different color fluorochrome. This product is intended for use as a quality control reagent to monitor the levels of nonspecific antibody binding in cell surface staining procedures which use CYTO-STAT® triCHROME™ Monoclonal Antibody Reagents comprised of CD45-FITC and two MsIgG1 subclass monoclonal antibodies conjugated to RD1 and PC5.
CD3+ and/or CD19+ lymphocyte percentages and absolute counts may be used as aids to evaluate immune competency underlying known or unknown disease states and to monitor lymphocyte levels following organ transplantation.
To illustrate, identification of abnormal levels of CD3+ lymphocytes may aid in the diagnosis and/or prognosis of unidentified disease conditions in patients with low white blood cell counts. Measurement of CD3+ and/or CD19+ lymphocytes, in conjunction with CD4+ (inducer) and CD8+ (suppressor/cytotoxic) T lymphocytes and corresponding T4/T8 ratios, may aid in the diagnosis and/or prognosis of immunodeficiency disease such as infection with human immunodeficiency virus (HIV), the etiologic agent of acquired immunodeficiency syndrome (AIDS). Altered percentages of CD3+ lymphocytes recorded following organ (for example, kidney, hear, liver, lung) transplantation suggests T and/or B Jymphocyte quantitation may be useful as an aid in monitoring these cellular populations.
As part of a Three Color Lymphocyte Immunophenotyping Panel which includes the NK (Natural Killer) lymphocyte reagent, CYTO-STAT® triCHROME™ CD45-FITC/CD56-RD1/CD3-PCS, CYTO-STAT® triCHROME™ CD45-FITC/CD19-RDI/CD3-PC5 provides the ability to comprehensively identify and enumerate an individual's major lymphocyte subsets: T. B and NK. The reagent also functions as a quality control check for a specimen in terms of total lymphocyte percentage and CD3+ lymphocyte measurements across the panel.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
| Prescription Use | ✓ | OR | Over-The-Counter Use |
|---|---|---|---|
| (Per 21 CFR 801.109) |
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Clinical Laboratory Devices
| 510(k) Number | K982167 |
|---|---|
| --------------- | --------- |
510i4us2